Physician profile
Robert Carroll
NPI 1295875854
$2,894.18
in general payments reported to CMS, 2019-2025
27 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $53.55 · 2023: $470 · 2024: $876 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.72 |
| Education | $114.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,020.86 | 2024-2025 | Carvykti, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $276.37 | 2023-2025 | Calquence, Lynparza |
| Pfizer INC. | $220.46 | 2024-2025 | |
| Caris Mpi, INC. | $190.94 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $142.67 | 2024 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $138.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.86 | 2024 | Reblozyl |
| Adaptive Biotechnologies Corporation | $95.79 | 2025 | Clonoseq |
| Genmab U.S., INC. | $93.06 | 2023 | Epkinly |
| Array Biopharma INC | $89.59 | 2025 | Braftovi, Mektovi, Tukysa |
| Kite Pharma, INC. | $77.91 | 2025 | Yescarta |
| Menarini Silicon Biosystems, INC. | $60.18 | 2024 | |
| Aveo Pharmaceuticals, INC. | $41.16 | 2023 | Fotivda |
| Baxter Healthcare | $35.84 | 2023 | Perclot |
| Regeneron Healthcare Solutions, INC. | $33.86 | 2023 | Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.22 | 2023 | Keytruda, Lenvima |
| Celgene Corporation | $30.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.28 | 2024 | |
| Karyopharm Therapeutics INC. | $24.05 | 2023 | Xpovio |
| Genentech USA, INC. | $23.14 | 2022 | |
| Abbvie INC. | $22.69 | 2024 | |
| Daiichi Sankyo INC. | $21.59 | 2023 | Enhertu |
| Kyowa Kirin, INC. | $16.20 | 2023 | Poteligeo |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Astellas Pharma US INC | $15.53 | 2023 | Xospata |
| Viiv Healthcare Company | $14.75 | 2023 | Dovato |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.